Brokerages Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $6.75

Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $6.75.

Several analysts recently commented on the company. Wall Street Zen raised Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Bank of America reduced their target price on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Friday.

Acumen Pharmaceuticals News Roundup

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Analyst and institutional support — ABOS carries a consensus “Moderate Buy” from sell‑side analysts with a consensus price target near $6.75, and several institutions have recently built or increased stakes (Hudson Bay, SG Americas, Susquehanna, Bank of America). This underpins longer‑term demand and may limit downside. MarketBeat Coverage
• Neutral Sentiment: Short‑interest data is reported as effectively zero for Jan. 12, but the published figures contain inconsistencies (NaN); the short‑interest snapshot is unreliable and should not be relied on for explaining intraday moves. Monitor future updates for clarity.
• Neutral Sentiment: Insiders retain large holdings — despite recent sales, CEO Daniel O’Connell still owns ~593k shares, CFO Matt Zuga ~210k and COO Russell Barton ~123k. Large remaining insider stakes can be seen as alignment with shareholders even after sales.
• Negative Sentiment: Clustered insider selling — multiple senior executives sold shares between Jan. 5–12. CEO Daniel O’Connell sold ~26,472 shares across three trades (avg prices roughly $1.73–$1.82), CFO Matt Zuga sold 6,888 shares at $1.82 (and additional small sales earlier in the week), and COO Russell Barton sold 3,530 shares at $1.86. The concentration of sales (roughly ~37k shares total) is likely weighing on near‑term sentiment. SEC filings and press coverage: SEC Form 4 AmericanBankingNews: CEO sale
• Negative Sentiment: CFO’s repeated small sales — Matt Zuga executed multiple sales in early January (Jan. 5–8) at prices between ~$1.96–$1.82, totaling roughly $40k–$45k across those trades; repeated disposals can be interpreted negatively by active traders. Coverage: InsiderTrades alert

Acumen Pharmaceuticals Price Performance

Shares of ABOS stock opened at $1.73 on Friday. Acumen Pharmaceuticals has a 52 week low of $0.86 and a 52 week high of $2.46. The stock has a market capitalization of $104.79 million, a PE ratio of -0.78 and a beta of 0.23. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. The stock’s fifty day moving average is $1.93 and its 200-day moving average is $1.69.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.19. Equities research analysts expect that Acumen Pharmaceuticals will post -1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In other Acumen Pharmaceuticals news, CEO Daniel Joseph Oconnell sold 37,755 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total value of $75,132.45. Following the completion of the sale, the chief executive officer owned 619,982 shares in the company, valued at $1,233,764.18. This trade represents a 5.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold 127,620 shares of company stock worth $244,607 in the last 90 days. 7.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ABOS. Jacobs Levy Equity Management Inc. bought a new stake in Acumen Pharmaceuticals in the third quarter valued at approximately $27,000. Susquehanna International Group LLP raised its stake in Acumen Pharmaceuticals by 26.5% in the 3rd quarter. Susquehanna International Group LLP now owns 214,440 shares of the company’s stock valued at $367,000 after acquiring an additional 44,902 shares during the period. Bank of America Corp DE raised its position in shares of Acumen Pharmaceuticals by 45.4% in the third quarter. Bank of America Corp DE now owns 213,729 shares of the company’s stock valued at $365,000 after purchasing an additional 66,720 shares during the period. Bridgeway Capital Management LLC lifted its stake in shares of Acumen Pharmaceuticals by 65.1% during the 3rd quarter. Bridgeway Capital Management LLC now owns 190,171 shares of the company’s stock worth $325,000 after buying an additional 75,000 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Acumen Pharmaceuticals during the 3rd quarter worth about $691,000. Institutional investors own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.